November 23, 2011
The University of North Carolina at Chapel Hill Board of Trustees has approved the promotion of Stephen Frye, PhD, to the rank of full professor with tenure in the UNC Eshelman School of Pharmacy.
Frye is the director of the School’s Center for Integrative Chemical Biology and Drug Discovery, a research group bringing dedicated medicinal chemistry expertise to bear on biological targets of therapeutic relevance under investigation by UNC faculty. CIBDD project teams work with other groups on campus to move potential drug targets through the drug discovery and development process.
“This promotion is due recognition of the impressive contribution Dr. Frye has made to the School and to the advancement of cancer research here at Carolina. He had a highly distinguished career in the industry and has rapidly achieved success in the academic environment in the most impactful way,” says Bob Blouin, PharmD, dean of the School and Vaughn and Nancy Bryson Distinguished Professor.
Frye joined the School’s Division of Chemical Biology and Medicinal Chemistry in 2007 after a twenty-year career with GlaxoSmithKline. He is co-inventor of GSK’s Avodart, a drug used to shrink an enlarged prostate gland that is also under study for prevention of prostate cancer. He also led the department at GSK’s Research Triangle Park facility that discovered the compound that became the breast-cancer drug Tykerb.
In October 2010, the National Cancer Institute awarded $2.4 million in contracts to two teams of UNC scientists to establish the North Carolina Comprehensive Chemical Biology Center tasked to develop drugs for treating brain tumors and childhood leukemia. Frye is the lead principal investigator for the NCI center.
Latest News
Dean Angela Kashuba receives Carolina Alumni Faculty Service Award
RASP poster presentations capture student research
